ETFs with ISIS as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.4%||PowerShares Dynamic Biotech &Genome (PBE)||+2.59 (7.86%)|
|2.21%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+0.88 (0.73%)|
|0.47%||iShares Russell 2000 Growth Index Fund (IWO)||+8.04 (6.69%)|
|0.43%||Vanguard Russell 2000 Growth ETF (VTWG)||+5.92 (6.77%)|
|0.24%||iShares Russell 2000 Index Fund (IWM)||+5.07 (4.85%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. Our strategy is to do what we do best—to discover unique antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases, including cardiovascular, severe and rare, neurologic and metabolic diseases and cancer. Our partnering strategy provides us the flexibility to license each of our drugs at the optimal time to maximize the near- and long-term value of each drug. In this way, we can expand our pipeline and our partners’ pipelines with antisense drugs that address significant medical needs while remaining small and focused. ... More ...